scholarly article | Q13442814 |
P356 | DOI | 10.1128/AAC.44.7.1977-1979.2000 |
P8608 | Fatcat ID | release_chsjltlzk5hrtpxqs4tnyclrdm |
P932 | PMC publication ID | 89996 |
P698 | PubMed publication ID | 10858365 |
P2093 | author name string | A M Hirschl | |
M Wimmer | |||
M L Rotter | |||
A Makristathis | |||
P Apfalter | |||
P2860 | cites work | In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents | Q28379204 |
Linezolid activity compared to those of selected macrolides and other agents against aerobic and anaerobic pathogens isolated from soft tissue bite infections in humans | Q33976974 | ||
In vitro activities of linezolid against important gram-positive bacterial pathogens including vancomycin-resistant enterococci | Q33977497 | ||
Antimicrobial susceptibility testing of Helicobacter pylori in a large multicenter trial: the MACH 2 study | Q33978090 | ||
The pharmacologic and bacteriologic properties of oxazolidinones, a new class of synthetic antimicrobials. | Q34747691 | ||
In vitro antimicrobial activities and spectra of U-100592 and U-100766, two novel fluorinated oxazolidinones | Q35123200 | ||
In vitro activities of the oxazolidinone antibiotics U-100592 and U-100766 against Staphylococcus aureus and coagulase-negative Staphylococcus species | Q35132865 | ||
Gastric diffusion of antibiotics used against Helicobacter pylori | Q41744415 | ||
Antibiotic resistance in Helicobacter pylori: implications for therapy | Q50128865 | ||
Lack of effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia. Omeprazole plus Clarithromycin and Amoxicillin Effect One Year after Treatment (OCAY) Study Group. | Q53564053 | ||
Will Helicobacter pylori be the next organism for which we will have exhausted our treatment options? | Q54098348 | ||
The MACH2 study: Role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies | Q61960641 | ||
Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. European Helicobacter Pylori Study Group | Q73634127 | ||
Symptomatic benefit from eradicating Helicobacter pylori infection in patients with nonulcer dyspepsia | Q77716745 | ||
P433 | issue | 7 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | clarithromycin | Q118551 |
metronidazole | Q169569 | ||
Helicobacter pylori | Q180556 | ||
amoxicillin | Q201928 | ||
linezolid | Q411377 | ||
P304 | page(s) | 1977-1979 | |
P577 | publication date | 2000-07-01 | |
P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
P1476 | title | In vitro activities of linezolid alone and in combination with amoxicillin, clarithromycin, and metronidazole against Helicobacter pylori | |
P478 | volume | 44 |
Q64243638 | In Vitro Activity of 3-Bromopyruvate, an Anticancer Compound, Against Antibiotic-Susceptible and Antibiotic-Resistant Strains |
Q35014416 | In vitro activities of linezolid combined with other antimicrobial agents against Staphylococci, Enterococci, Pneumococci, and selected gram-negative organisms |
Q46497875 | In vitro activity of fosfomycin alone and in combination with amoxicillin, clarithromycin and metronidazole against Helicobacter pylori compared with combined clarithromycin and metronidazole |
Q33183184 | Oxazolidinone antibiotics. |
Q24530627 | Sulforaphane inhibits extracellular, intracellular, and antibiotic-resistant strains of Helicobacter pylori and prevents benzo[a]pyrene-induced stomach tumors |
Search more.